

# Bereskin & Parr



Barristers and Solicitors/ Patent and Trade Mark Agents  
Practice Restricted to Intellectual Property Law

April 9, 2001

Anita Nador B.A. (Molec. Biophys./Biochem), LL.B.  
416 957 1684 anador@bereskinparr.com

Our Reference: 11014-24

The Commissioner of Patents  
and Trademarks  
Washington, D.C.  
U.S.A. 20231

Dear Sir:

**Re: U.S. Regular Patent Application  
Claiming Priority from U.S. Provisional Patent Application No. 60/195,456**  
**Entitled: Immunogenic Peptides Derived From Prostate-  
Specific Antigen (PSA) and Uses Thereof**  
**Inventors: Artur Pedyczak, Pele Chong, Charles D.Y. Sia**

Applicants are submitting the above-identified patent application for filing at the United States Patent and Trademark Office.

Applicants are submitting herewith (1) a Sequence Listing in paper form; (2) a Sequence Listing in computer readable form (a 3.5" floppy diskette) in the ASCII format and (3) a statement (set forth below) that the paper form and the computer readable form of the Sequence Listing are the same.

In accordance with the requirements of 37 C.F.R. 1.821-1.825 the undersigned verifies that the paper form of the Sequence Listing and the computer readable form of the Sequence Listing are the same.

Respectfully submitted

**ARTHUR PEDYCZAK, PELE CHONG  
CHARLES D.Y. SIA**

  
Anita Nador  
Registration No. 47,366  
BERESKIN & PARR  
(Agents for the Applicants)

Enclosure

SEQUENCE LISTING

<110> Chong, Pele  
Pedyczak, Artur  
Sia, Charles Dwo Yuan

<120> Immunogenic Peptides Derived from Prostate-Specific Antigen (PSA) and  
Uses Thereof

<130> 11014-24

<150> US 60/195,456  
<151> 2000-04-10

<160> 12

<170> PatentIn version 3.0

<210> 1  
<211> 8  
<212> PRT  
<213> Artificial

<220>  
<223> CLP313  
<400> 1

Met Trp Val Pro Val Val Phe Leu  
1 5

<210> 2  
<211> 9  
<212> PRT  
<213> Artificial

<220>  
<223> CLP314  
<400> 2

Val Leu Val His Pro Gln Trp Val Leu  
1 5

<210> 3

```

<211> 9
<212> PRT
<213> Artificial

<220>
<223> CLP316
<400> 3

Lys Leu Gln Cys Val Asp Leu His Val
1 5

<210> 4
<211> 9
<212> PRT
<213> Artificial

<220>
<223> CLP315
<400> 4

Asp Leu Pro Thr Gln Glu Pro Ala Leu
1 5

<210> 5
<211> 9
<212> PRT
<213> Artificial

<220>
<223> CLP317
<400> 5

Asp Leu His Val Ile Ser Asn Asp Val
1 5

<210> 6
<211> 9
<212> PRT
<213> Artificial

<220>
<223> CLP320
<400> 6

Pro Leu Tyr Asp Met Ser Leu Leu Lys
1 5

```

<210> 7  
<211> 24  
<212> DNA  
<213> Artificial

<220>  
<223> CLP313  
<400> 7  
atgtgggtcc cgggttgttctt cctc

<210> 8  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> CLP314  
<400> 8  
gttctgggtgc accccccatgt ggtccctc

<210> 9  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> CLP316  
<400> 9  
aaaccttcaatgt gtgtggacccatgttt

<210> 10  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> CLP315  
<400> 10  
gacacctggccca cccaggagcc agcactg

<210> 11

```
<211> 27
<212> DNA
<213> Artificial

<220>
<223> CLP317
<400> 11
gacctccatg tttatccaa tgacgtg
```

27

<210> 12  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> CLP320  
<400> 12  
ccgcctctacg atatgagct cctgaa

27